Effect of Aidi injection plus transarterial chemoembolization on primary hepatic carcinoma: a systematic review and Meta-analysis

Shen, Zhen; Gu, Wei; Cheng, Haibo; Shen, Weixing; Sun, Dongdong; Zeng, Yun; Tao, Lihuiping; Mian-hua, WU

doi:10.1016/s0254-6272(17)30310-2

Cited by 7 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo experiments showed that Aidi injection had obvious inhibitory effect on S180 and H22 solid tumors in mice and could enhance the nonspecific and specific immune function of mice. [28] Similarly, in this study, it was found that the 1-year survival rate of patients with single medicine combined with TACE was significantly prolonged among patients with single medicine and mixed Chinese medicine preparations, with OR = 2.60, 95% CI (1.62-4.18), P = 0 < .01. On the contrary, mixed medicine combined with TACE had no such effect.…”

Section: Discussionsupporting

confidence: 60%

“…[28] Dong and Meng also found similar results. [28] However, Li, Yang, Dong, Xue, etc. think that the combination therapy has no significant difference in prolonging the 1-year survival rate.…”

Section: Discussionsupporting

confidence: 55%

“…Wang think that Aidi injection combined with TACE can improve the 1-year survival rate of patients. [28] Dong and Meng also found similar results. [28] However, Li, Yang, Dong, Xue, etc.…”

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of Chinese Medicines combined with transarterial chemoembolization on primary hepatic carcinoma: A systematic review and meta-analysis

Shan

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: To systematically evaluate the survival rate and postoperative adverse reactions of patients with hepatocellular carcinoma treated with traditional Chinese medicine combined with TACE by meta-analysis. Methods: Four major literature databases (Cochrane Library, Embase, PubMed, and Web of Science) were retrieved to collect published English articles since 2009. After determining the random effect model or fixed utility model based on a heterogeneity test, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Results: This meta-analysis included 8 prospective studies published between 2009 and 2019. Due to moderate heterogeneity (P < .05, I 2 = 54.8%), Therefore, the random effect model is used to analyze the data, so as to explore the relationship between CMs combined with TACE treatment and survival rate and postoperative adverse reactions. All the comprehensive test results show that there is a statistical significance between CMs combined with TACE treatment and survival rate. (OR = 1.88, 95% CI 1.34–2.64, P = .03). Then subgroup analysis and sensitivity analysis were carried out. The results indicated that the overall results ranged from 1.12(95% CI = 1.03–1.11) to 1.21(95% CI = 1.22–1.33). Conclusions: The 1-year survival rate of patients treated with traditional Chinese medicine TACE is a protective factor, and the quality score included in the study affects the evaluation of the effective dose. At the same time, traditional Chinese medicine combined with TACE has nothing to do with the reduction of postoperative complications.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionsupporting

confidence: 55%

“…Wang think that Aidi injection combined with TACE can improve the 1-year survival rate of patients. [28] Dong and Meng also found similar results. [28] However, Li, Yang, Dong, Xue, etc.…”

Section: Discussionmentioning

confidence: 53%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Chinese Medicines combined with transarterial chemoembolization on primary hepatic carcinoma: A systematic review and meta-analysis

Shan

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…Thus, 57 potentially studies were selected for full-text screening. Of these, 30 articles were excluded for the following reasons: studies were not systematic reviews/meta-analyses ( n = 3) [36–38]; studies did not evaluate clinical outcomes ( n = 7) [39–45]; Aidi combine with radiotherapy or targeted therapy ( n = 8) [46–53]; data unavailable ( n = 6) [54–59]; and studies included other TCM ( n = 6) [60–65]. Finally, a total of 27 systematic reviews/meta-analyses were included in this overview [7–33].…”

Section: Resultsmentioning

confidence: 99%

Aidi injection combined with chemotherapy in the treatment of cancer patients: a systematic review of systematic reviews and meta-analyses

et al. 2021

View full text Add to dashboard Cite

The objective of the study was to evaluate and summarize the evidence from systematic reviews and meta-analyses regarding the efficacy and safety of Aidi injection combined with chemotherapy in the treatment of cancer patients. PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Chong qing VIP databases, and Wanfang databases were searched for systematic reviews/meta-analyses on the topic of Aidi treating cancer patients published from inception to 20 December 2020. Google Scholar and OpenGrey were searched for grey literature and International Prospective Register of Systematic Reviews for ongoing reviews. Two investigators independently selected eligible studies, extracted data, and assessed the methodological quality of included systematic reviews/meta-analyses using the measurement tool to assess systematic reviews 2 (AMSTAR-2) tool, and the strength of evidence was assessed with the grade of recommendation, assessment, development, and evaluation (GRADE) system. Twenty-seven systematic reviews/meta-analyses were identified in the study. The methodological quality of all 27 systematic reviews/meta-analyses were critically low when evaluated by AMSTAR-2, and the evidence quality of all outcomes rated as either low or very low based on the GRADE system. The available evidence is currently insufficient to support or refute the use of Aidi in the treatment of cancer patients, thus high-quality trials with large sample sizes are needed to explore its efficacy and safety in cancer patients.

show abstract

Asperulosidic Acid Restrains Hepatocellular Carcinoma Development and Enhances Chemosensitivity Through Inactivating the MEKK1/NF-κB Pathway

Qiu

2023

Appl Biochem Biotechnol

View full text Add to dashboard Cite

Effect of Aidi injection plus transarterial chemoembolization on primary hepatic carcinoma: a systematic review and Meta-analysis

Cited by 7 publications

References 9 publications

Effect of Chinese Medicines combined with transarterial chemoembolization on primary hepatic carcinoma: A systematic review and meta-analysis

Effect of Chinese Medicines combined with transarterial chemoembolization on primary hepatic carcinoma: A systematic review and meta-analysis

Aidi injection combined with chemotherapy in the treatment of cancer patients: a systematic review of systematic reviews and meta-analyses

Asperulosidic Acid Restrains Hepatocellular Carcinoma Development and Enhances Chemosensitivity Through Inactivating the MEKK1/NF-κB Pathway

Contact Info

Product

Resources

About